2022 Fiscal Year Final Research Report
Strategy for the treatment of neurodegeneration associated with obesity and hyperglycemia using antimiR
Project/Area Number |
20K07296
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 48030:Pharmacology-related
|
Research Institution | Teikyo University |
Principal Investigator |
Aoyama Koji 帝京大学, 医学部, 教授 (00420943)
|
Project Period (FY) |
2020-04-01 – 2023-03-31
|
Keywords | グルタチオン |
Outline of Final Research Achievements |
Previous studies have proposed a link between obesity, hyperglycemia, oxidative stress in the brain, and the pathogenesis of dementia. In the brain, GTRAP3-18, a protein expressed in neurons, plays a crucial role in regulating the synthesis of the essential antioxidant glutathione (GSH), as well as modulating food intake and blood glucose levels. The expression of GTRAP3-18 in the brain is regulated by microRNA miR-96-5p. This study aimed to investigate the effects of intranasal administration of antimiR-96-5p, a nucleic acid drug designed to inhibit miR-96-5p, in an obesity and diabetes mouse model. Our findings suggest that intranasal administration of antimiR-96-5p may elevate GSH levels in the brains of obesity and diabetes model (ob/ob) mice.
|
Free Research Field |
神経科学
|
Academic Significance and Societal Importance of the Research Achievements |
本課題は、認知症発症の危険因子と考えられる肥満・糖尿病が脳内で引き起こす酸化ストレスを抑制するため、新たな遺伝子治療薬となりうる「microRNA標的核酸分子」を動物実験に応用した研究である。脳内における重要な抗酸化物質であるグルタチオンの産生を促進すると同時に摂食抑制・血糖値低下をもたらすタンパク質を制御しているmicroRNAの働きを抑制する核酸薬antimiRを投与し、肥満・糖尿病を改善すると同時に認知症の発症および病態進行を抑制する新たな治療戦略に基づいた研究である。
|